CN105228633A - 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 - Google Patents

用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 Download PDF

Info

Publication number
CN105228633A
CN105228633A CN201480018525.6A CN201480018525A CN105228633A CN 105228633 A CN105228633 A CN 105228633A CN 201480018525 A CN201480018525 A CN 201480018525A CN 105228633 A CN105228633 A CN 105228633A
Authority
CN
China
Prior art keywords
compound
disease
acid
compositions
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480018525.6A
Other languages
English (en)
Chinese (zh)
Inventor
G.戈弘罗马尼罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUEVAS ALTERNATIVAS NATURALES SAP I DE CV
Original Assignee
NUEVAS ALTERNATIVAS NATURALES SAP I DE CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/751,429 external-priority patent/US20130136725A1/en
Application filed by NUEVAS ALTERNATIVAS NATURALES SAP I DE CV filed Critical NUEVAS ALTERNATIVAS NATURALES SAP I DE CV
Publication of CN105228633A publication Critical patent/CN105228633A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480018525.6A 2013-01-28 2014-01-28 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物 Pending CN105228633A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/751,429 US20130136725A1 (en) 2002-06-19 2013-01-28 Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US13/751429 2013-01-28
PCT/MX2014/000029 WO2014116097A2 (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox

Publications (1)

Publication Number Publication Date
CN105228633A true CN105228633A (zh) 2016-01-06

Family

ID=51228167

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480018525.6A Pending CN105228633A (zh) 2013-01-28 2014-01-28 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物

Country Status (10)

Country Link
EP (1) EP2949332A4 (enExample)
JP (1) JP2016508996A (enExample)
KR (1) KR20160140331A (enExample)
CN (1) CN105228633A (enExample)
AU (1) AU2014210447A1 (enExample)
BR (1) BR112015017440A2 (enExample)
CA (1) CA2898596A1 (enExample)
HK (1) HK1217175A1 (enExample)
MX (1) MX2015009403A (enExample)
WO (1) WO2014116097A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113347950A (zh) * 2019-01-19 2021-09-03 红婴生物科技股份有限公司 眼用透镜、药学组合物及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202502A (en) 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
CA3171332A1 (en) 2020-03-16 2021-09-23 Andreas Bergmann Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
JPS59118709A (ja) 1982-12-27 1984-07-09 Suntory Ltd 効力を増強しかつ低毒化せしめた抗腫瘍組成物
DE3419686A1 (de) 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
IL81166A (en) 1987-01-05 1990-03-19 Kaplan Ephraim Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium
JP5063878B2 (ja) * 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
WO2011005841A1 (en) * 2009-07-08 2011-01-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JENNIFER GREBOW: "Tablets and Capsules:Special Delivery", 《HTTP://WWW.PHYSICIANSPRACTICE.COM/MAGAZINE/TABLETS-AND-CAPSULES-SPECIAL-DELIVERY 》 *
无: "Acid Armor", 《HTTPS://WWW.ARTHURANDREW.COM/BLOGS/NEWS/57279685-ACID-ARMOR》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113347950A (zh) * 2019-01-19 2021-09-03 红婴生物科技股份有限公司 眼用透镜、药学组合物及其用途

Also Published As

Publication number Publication date
MX2015009403A (es) 2017-07-04
CA2898596A1 (en) 2014-07-31
JP2016508996A (ja) 2016-03-24
BR112015017440A2 (pt) 2017-07-11
EP2949332A4 (en) 2016-07-27
HK1217175A1 (zh) 2016-12-30
EP2949332A2 (en) 2015-12-02
WO2014116097A2 (es) 2014-07-31
AU2014210447A1 (en) 2015-08-20
WO2014116097A3 (es) 2014-12-04
KR20160140331A (ko) 2016-12-07

Similar Documents

Publication Publication Date Title
CN105228633A (zh) 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
Yeom et al. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration
CN104080339B (zh) 高生物利用度的零价硫的制备和组合物及其用途
CN109310653A (zh) 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
US20130136725A1 (en) Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
BRPI0620425B1 (pt) Composição para nutrição parenteral, método para preparar a mesma, uso, e, kit
EP4157326A1 (en) Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system
JP2008285463A (ja) 関節症・リウマチ・膠原病の治療薬
BRPI0608512A2 (pt) misturas de vitaminas
US20140294799A1 (en) Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment
CN109663123A (zh) 一种改善肝损伤及机体疲劳的胶囊及其制备方法
Tulp et al. Effects of the Phytopolyphenol Resveratrol as a Therapeutic Adjunct in Sickle Cell Disease (SCD) and β-thalassemia Management
Tulp et al. Can trans-3’5’4-trihydroxystilbene (resveratrol) become an effective adjunct in the treatment of sickle cell disease
Hussain et al. Vitamins and SARS-CoV-2
CN107174587A (zh) 丁二磺酸腺苷蛋氨酸在抗辐射功效方面的应用
WO2021260671A1 (fr) Extrait d'un champignon de la famille des boletus fungi pour son utilisation notamment dans la prévention de la maladie covid 19
Dean Mitochondrial Restoration, Part II: Restoring Mitochondrial Function and Bio-Energetics
CH690318A5 (fr) Composition d'additif nutritionnel pour administration intraveineuse.
Dean Restoring Mitochondrial Function and Bio-Energetics
CN102716220A (zh) 一种水包油型复方螺内酯纳米乳药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217175

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160106

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1217175

Country of ref document: HK